BACKGROUND: Griscelli syndrome type 2 (GS2), the X-linked lymphoproliferative (XLP) and the Chédiak-Higashi (CHS) syndromes are diseases that all may develop hemophagocytic syndromes. We wanted to investigate whether the treatment protocols for hemophagocytic lymphohistiocytosis (HLH) can also be used for these syndromes. PROCEDURE: In the HLH-94/HLH-2004 treatment study registries, we evaluated all patients with GS2 (n = 5), XLP (n = 2) or CHS (n = 2) treated between 1994 and 2004. RESULTS: All patients responded to the therapy, and all are alive but one (suffering from CHS), with a mean follow-up of 5.6 years. All GS2, one XLP and one CHS patient underwent hematopoietic stem cell transplant. Mean follow-up post transplant was 6.0 years. Six of the seven transplanted children achieved non-active disease status at the time for SCT. Neurological sequelae were reported in all, except for the XLP patients. CONCLUSIONS: Our results indicate that HLH treatment can be an effective first line treatment to induce remission in patients with GS2, XLP and CHS that have developed a hemophagocytic syndrome. We suggest that these patients should be included as a separate cohort in the international HLH study. (c) 2008 Wiley-Liss, Inc.
BACKGROUND:Griscelli syndrome type 2 (GS2), the X-linked lymphoproliferative (XLP) and the Chédiak-Higashi (CHS) syndromes are diseases that all may develop hemophagocytic syndromes. We wanted to investigate whether the treatment protocols for hemophagocytic lymphohistiocytosis (HLH) can also be used for these syndromes. PROCEDURE: In the HLH-94/HLH-2004 treatment study registries, we evaluated all patients with GS2 (n = 5), XLP (n = 2) or CHS (n = 2) treated between 1994 and 2004. RESULTS: All patients responded to the therapy, and all are alive but one (suffering from CHS), with a mean follow-up of 5.6 years. All GS2, one XLP and one CHSpatient underwent hematopoietic stem cell transplant. Mean follow-up post transplant was 6.0 years. Six of the seven transplanted children achieved non-active disease status at the time for SCT. Neurological sequelae were reported in all, except for the XLPpatients. CONCLUSIONS: Our results indicate that HLH treatment can be an effective first line treatment to induce remission in patients with GS2, XLP and CHS that have developed a hemophagocytic syndrome. We suggest that these patients should be included as a separate cohort in the international HLH study. (c) 2008 Wiley-Liss, Inc.
Authors: Claire Booth; Kimberly C Gilmour; Paul Veys; Andrew R Gennery; Mary A Slatter; Helen Chapel; Paul T Heath; Colin G Steward; Owen Smith; Anna O'Meara; Hilary Kerrigan; Nizar Mahlaoui; Marina Cavazzana-Calvo; Alain Fischer; Despina Moshous; Stephane Blanche; Jana Pachlopnik Schmid; Jana Pachlopnick-Schmid; Sylvain Latour; Genevieve de Saint-Basile; Michael Albert; Gundula Notheis; Nikolaus Rieber; Brigitte Strahm; Henrike Ritterbusch; Arjan Lankester; Nico G Hartwig; Isabelle Meyts; Alessandro Plebani; Annarosa Soresina; Andrea Finocchi; Claudio Pignata; Emilia Cirillo; Sonia Bonanomi; Christina Peters; Krzysztof Kalwak; Srdjan Pasic; Petr Sedlacek; Janez Jazbec; Hirokazu Kanegane; Kim E Nichols; I Celine Hanson; Neena Kapoor; Elie Haddad; Morton Cowan; Sharon Choo; Joanne Smart; Peter D Arkwright; Hubert B Gaspar Journal: Blood Date: 2010-10-06 Impact factor: 22.113
Authors: Elisabet Bergsten; AnnaCarin Horne; Maurizio Aricó; Itziar Astigarraga; R Maarten Egeler; Alexandra H Filipovich; Eiichi Ishii; Gritta Janka; Stephan Ladisch; Kai Lehmberg; Kenneth L McClain; Milen Minkov; Scott Montgomery; Vasanta Nanduri; Diego Rosso; Jan-Inge Henter Journal: Blood Date: 2017-09-21 Impact factor: 22.113
Authors: Helena Trottestam; Annacarin Horne; Maurizio Aricò; R Maarten Egeler; Alexandra H Filipovich; Helmut Gadner; Shinsaku Imashuku; Stephan Ladisch; David Webb; Gritta Janka; Jan-Inge Henter Journal: Blood Date: 2011-09-06 Impact factor: 22.113
Authors: Inger Vedin; Tommy Cederholm; Yvonne Freund-Levi; Hans Basun; Anita Garlind; Gerd Faxén Irving; Maria Eriksdotter-Jönhagen; Lars-Olof Wahlund; Ingrid Dahlman; Jan Palmblad Journal: PLoS One Date: 2012-04-24 Impact factor: 3.240
Authors: James D Weisfeld-Adams; Lakshmi Mehta; Janet C Rucker; Francine R Dembitzer; Arnold Szporn; Fred D Lublin; Wendy J Introne; Vikas Bhambhani; Michael C Chicka; Catherine Cho Journal: Orphanet J Rare Dis Date: 2013-03-22 Impact factor: 4.123